Results 131 to 140 of about 23,261 (287)

Echinocandins Localized to the Target-Harboring Cell Surface Are Not Degraded but Those Entering the Vacuole Are

, 2022
Qais Z. Jaber, Dana Logviniuk, Adi Yona, Micha Fridman   +3 more
openalex   +1 more source

Rapid emergence of FKS mutations in Candida glabrata isolates in a peritoneal candidiasis

Medical Mycology Case Reports, 2017
We report a rapid acquisition of echinocandin resistance after 12 days of micafungin treatment, without prior exposure, in a patient with peritoneal candidiasis due to C. glabrata. Isolates recovered before and after treatment were compared by multilocus
Milène Sasso, Claire Roger, Laurence Lachaud   +2 more
doaj   +1 more source

Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis [PDF]

, 2017
The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds.
Ana C. A. de Paula e Silva, Ana M. Fusco-Almeida, Caroline B. Costa-Orlandi, Caroline M. Marcos, Haroldo C. de Oliveira, Liliana Scorzoni, Maria J. S. Mendes-Giannini, Patrícia A. Assato, Wanessa C. M. A. de Melo   +8 more
core   +1 more source

Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model

Journal of Antimicrobial Chemotherapy, 2018
Background Multiple cases of Candida auris infection have been reported with high mortality rates owing to its MDR nature. Rezafungin (previously CD101) is a novel echinocandin with enhanced stability and pharmacokinetics that achieves high plasma drug ...
C. Hager, Emily L. Larkin, L. Long, M. Ghannoum   +3 more
semanticscholar   +1 more source

Recent trends in molecular diagnostics of yeast infections : from PCR to NGS [PDF]

, 2019
The incidence of opportunistic yeast infections in humans has been increasing over recent years. These infections are difficult to treat and diagnose, in part due to the large number and broad diversity of species that can underlie the infection.
Arastehfar, A, Boekhout, T, Buda De Cesare, G, Butler, G, Dolk, E, Gabaldón, Tony, Hafez, A, Hagen, F, Hovhannisyan, H, Hube, B, Iracane, E, Kostrzewa, M, Lackner, M, Lass-Flörl, C, Llorens, C, Mixão, V, Munro, C, Oliveira-Pacheco, J, OPATHY Consortium, the, Pekmezovic, M, Pérez-Hansen, A, Rodriguez Sánchez, Antonio, Sauer, FM, Sparbier, K, Stavrou, AA, Vaneechoutte, Mario, Vatanshenassan, M   +26 more
core   +2 more sources

A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans

mBio, 2019
Cryptococcus neoformans is the leading cause of fungal meningitis, accounting for ∼15% of HIV/AIDS-related deaths, but treatment options for cryptococcosis are limited.
Chengjun Cao, Yina Wang, Seema Husain, P. Soteropoulos, C. Xue   +4 more
semanticscholar   +1 more source

Echinocandin Resistance in Two Candida haemulonii Isolates from Pediatric Patients [PDF]

, 2012
We report 3 cases of patients with Candida haemulonii isolates that were obtained from hemocultures. in 2 of the 3 cases, isolates exhibited resistance to echinocandins and fluconazole.
Azevedo Melo, Analy Salles de, Burger, Marion, Dalla-Costa, Libera Maria, Motta, Fabio de Araujo, Muro, Marisol Dominguez   +4 more
core   +1 more source

Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: Fifteen years of interpretation and assessment.

Medical Mycology, 2019
Candidemia is widely reported as the fourth most common form of bloodstream infection worldwide. Reports of breakthrough cases of candidemia are increasing, especially in the context of a move away from azole antifungals as prophylactic or first line ...
M. Fraser, A. Borman, R. Thorn, Lynne M. Lawrance   +3 more
semanticscholar   +1 more source

Comparative evaluation of Sensititre YeastOne and CLSI M38-Ed3 reference method for determining echinocandin minimum effective concentrations against Aspergillus isolates

Microbiology Spectrum
The minimum inhibitory concentration (MIC) of echinocandins against Aspergillus spp. does not represent the actual inhibition threshold of echinocandins.
Assaf Potruch, Hila Elinav, Matan J. Cohen, Alexander Rouvinski, Itzhack Polacheck, Maya Korem   +5 more
doaj   +1 more source

Drug Resistance in Eukaryotic Microorganisms [PDF]

, 2016
Eukaryotic microbial pathogens are major contributors to illness and death globally. Although much of their impact can be controlled by drug therapy as with prokaryotic microorganisms, the emergence of drug resistance has threatened these treatment ...
A Abdolrasouli, A Cassone, A Chowdhary, A Ecker, A Heinberg, A Kulshrestha, A Mbengue, A Mukherjee, A Selmecki, A Selmecki, A Trochine, AC Coelho, AF Cowman, AF Cowman, AH Fairlamb, AH Fairlamb, AJ Kazibwe, AM Abd-Alla, AM Dondorp, AM Mejia, AY Sokolova, B Chawla, B Gourbal, B Zingales, BD Alexander, BJ Kullberg, BK Kubata, BM Mony, BS Hall, BS Hall, BS McGwire, C Amaratunga, C Amaratunga, C Brochu, C Costa, C Mathieu, C Sisowath, C Wongsrichanalai, CA Morillo, CD Goodman, CF Oliva, CP Sanchez, CP Sanchez, D Begolo, D Rojo, DA Fidock, DS Guttery, DS Perlin, DW Denning, E Castanys-Munoz, E Chatelain, E Kussell, E Matovu, E Shor, E Snelders, E Snelders, E Vermeulen, E Wang, F Ariey, F Nosten, FC Odds, FE Graf, FE Graf, FJ Perez-Victoria, FJ Perez-Victoria, FJ Perez-Victoria, FM Fernandez, G Awasthi, G Blum, G Priotto, GA Canuto, GA Pankey, GM Nayyar, GW Rose, H Noedl, HL Callahan, HM Andrade, HY Sun, I Keren, I Molina, IH Cheeseman, IM Vincent, IM Vincent, IM Vincent, J Hemingway, J Robays, J Song, J Straimer, J Yuan, JA Urbina, JA Urbina, JC Dias, JC Dias, JC Munday, JC Wootton, JI Manzano, JL Nishikawa, JM Perez-Victoria, JR Franco, JW van der Linden, K El Fadili, K Lewis, K Seifert, KC Gray, KJ Kwon-Chung, KW Dantzler, L Denoeud-Ndam, L Glover, LE Cowen, LE Cowen, M Berg, M Ghorbal, M Maharjan, M Manske, M Plourde, M Rakotomanga, M Rakotomanga, M Venkatesan, M Woolhouse, M Woolhouse, MA Pfaller, MB Rogers, MC Brotherton, MD LaFleur, MD LaFleur, MK Kinga, MK Laufer, MR Perry, MR Perry, MR Perry, MT Duraisingh, MT Ferdig, N Baker, N Biyani, N Marquis, N Regev-Rudzki, N Rovira-Graells, NJ White, NR Cohen, NS Carter, O Epaulard, O Miotto, P Baiocco, P Maser, P Shaked-Mishan, P Vandeputte, P Wang, PE Verweij, PJ Hotez, PK Fyfe, PL Olliaro, PP Pyana, PY Mantel, R Kumar, R Mukhopadhyay, R Prasad, RD Cannon, S Alsford, S Decuypere, S Decuypere, S Dey, S Dey, S Imhof, S Kucharikova, S Leroux, S Mandal, S Mok, S Patterson, S Pelleau, S Pulcini, S Rijal, S Sundar, S Sundar, S Takala-Harrison, S Wyllie, S Wyllie, S Wyllie, S Wyllie, SA Flowers, SC Welburn, SD Singh, SE Kidd, SG Valderramos, SK Katiyar, SMF Murta, SR Meshnick, SR Wilkinson, TE Wellems, TE Wellems, TPC Dorlo, V Lutje, W Peters, Y Sterkers, Y Zhou   +193 more
core   +4 more sources